|Year : 2019 | Volume
| Issue : 1 | Page : 25-31
Comparative study of effectiveness of autologous serum and histaglobulin in autologous serum skin test positive and negative cases of chronic urticaria
Anamika Chaudhari, Hita Mehta, Neha Agrawal
Department of Dermatology, Venereology and Leprosy, Government Medical College, Sir. T. Hospital, Bhavnagar, Gujarat, India
|Date of Web Publication||12-Jun-2019|
Dr. Hita Mehta
201, Golden Arc Apartment, Atabhai Chowk, Bhavnagar, Gujarat
Source of Support: None, Conflict of Interest: None
AIMS AND OBJECTIVES: The aim of our study is to compare the effectiveness of autologous serum therapy (AST) with histaglobulin in patients of chronic urticaria.
MATERIALS AND METHODS: This was a prospective, comparative, randomized controlled, single-blinded study. Based on inclusion and exclusion criteria, patients were selected and divided into two groups by randomization. Autologous serum skin test was done in each patient irrespective of their groups. Group A (n = 30) received AST and Group B (n = 30) received histaglobulin. Patients' assessment was done every week for urticaria activity score (UAS) for 8 weeks.
STATISTICAL ANALYSIS: We used Mann–Whitney test to compare the means between two groups. Wilcoxon signed-rank test was used to compare pre- and posttreatment UAS scores.
RESULTS: Both therapies reduced UAS significantly (P = 0.01) at 8 weeks, and the reduction was observed every week. AST reduced UAS more than histaglobulin. However, within intergroup, difference was not significant. All patients had reduced severity of urticaria; however, complete remission (UAS = 0) was observed in three patients of Group A.
CONCLUSION: Group A (AST) showed statistically significant improvement than Group B (histaglobulin), but both showed a reduction in UAS with a longer treatment-free interval.
Keywords: Autologous serum skin test, chronic urticaria, histaglobulin, serum
|How to cite this article:|
Chaudhari A, Mehta H, Agrawal N. Comparative study of effectiveness of autologous serum and histaglobulin in autologous serum skin test positive and negative cases of chronic urticaria. Indian J Allergy Asthma Immunol 2019;33:25-31
|How to cite this URL:|
Chaudhari A, Mehta H, Agrawal N. Comparative study of effectiveness of autologous serum and histaglobulin in autologous serum skin test positive and negative cases of chronic urticaria. Indian J Allergy Asthma Immunol [serial online] 2019 [cited 2019 Oct 17];33:25-31. Available from: http://www.ijaai.in/text.asp?2019/33/1/25/260175
| Introduction|| |
Urticaria or hives (Latin “urtica” [to burn]) affects 0.5%–1% of the population at any given time. Patients of chronic urticaria suffer from irritable itch, waxing, and waning course and are also subjected to a huge antihistamine pill burden. Many studies compared the efficacy of various second-generation antihistamines as first-line treatment; however, their effectiveness is limited, so a modality that can provide extended relief and reduce antihistaminic load needs to be reaserched upon.
Autologous serum and histaglobulin have been tried for various autoimmune diseases., Autoreactive urticaria is a subgroup of chronic urticaria containing circulating functional autoantibodies and routinely diagnosed by autologous serum skin test (ASST). Effectiveness of autologous serum therapy (AST) was determined in this subgroup.,
Hence, we carried out the study to assess the effectiveness and safety of AST and histaglobulin as an immunological therapy.
| Materials and Methods|| |
The study was designed as a single-center, single-blinded, randomized controlled trial of 12-month duration; patients (>18 years) of either sex suffering from chronic urticaria attending the dermatology outpatient department of a tertiary care center, Sir T. Hospital, were included after written informed consent from all participants after obtaining approval from the Institutional Ethics Committee.
The patients of chronic urticaria taken as in whom itching and wheals occurring daily or near daily(≥3 times/week) for ≥6 weeks and had moderate and severe urticaria score [Figure 1]. Pregnant and lactating women, patients taking immunosuppressant drugs, patients with severe renal and cardiac diseases, patients who were inability to come for weekly follow-ups, and patients with coagulation defects and acute allergic symptoms were excluded from the study.
Sample size calculation
The sample size was calculated by Epi Info software (Atlanta, Georgia). Totally 72 participants included in our study; among them, 12 not give consent, so we enrolled 60 patients.
Patients were asked to discontinue any antihistamines 2 days before the test and at the start of the therapy. A thorough clinical examination was done to note any associated comorbidity, and relevant investigations were done for their confirmation.
Patients were randomized into two treatment groups: Group A and Group B using a computer-generated random number table in 1:1 ratio. ASST was performed in all study participants, and the result was recorded after 30 min (as detailed below). The patients of Groups A and B received AST and injection histaglobulin, respectively. Patients in both treatment groups were instructed to consume tablet levocetirizine in an on-demand basis. Any participant experiencing intolerable symptoms of urticaria was instructed to contact the investigator.
At each successive weekly follow-up, AST or histaglobulin was given for 8 consecutive weeks. Injectable hydrocortisone and chlorpheniramine maleate were kept as rescue medications. At all these eight follow-ups, UAS was noted. After 8 weeks, therapy was discontinued, and the patients were followed up for improvement or recurrence of symptoms weekly for the next 24 weeks. Levocetirizine was administered throughout the study period in on-demand basis even after the completion of AST injections and histaglobulin.
Autologous serum skin test
Five milliliters of venous blood of the patient was drawn with a sterile, disposable syringe from the antecubital vein in sterile vacutainer for serum collection. The blood was subjected to centrifugation using centrifuge machine at the rate of 2000 rpm for 10 min at room temperature. About 0.05 ml of the serum was injected immediately intradermally into the patient's left flexor forearm 2 inches below the antecubital crease and 0.05 ml sterile normal saline as negative control into the right forearm using 31-G sterile disposable insulin syringe.
A reading of the wheal was taken after 30 min and at 1 h. Patients having wheal of ≥1.5-mm diameter than that of controls with erythema were considered to be suffering from autoreactive urticaria (ASST positive) [Figure 2].
Group A – Autologous serum therapy
In Group A, 2 ml of the fresh serum separated from the patient's blood (as above) was given deep Intramuscular (IM) for 8 successive weeks.
In another group, 1-ml subcutaneous injection of histaglobulin which is a combination of human normal immunoglobulin (12 mg) and histamine dihydrochloride (0.15 mcg) was given for 8 weeks.
UAS is calculated from the number and size of wheals, intensity of pruritus, duration of persistence of lesions, frequency of appearance of lesions, and frequency of antihistamine use, with each parameter having a score of 0–3, maximum score being 18.
Vital signs and adverse events were assessed at every week of follow-up. Laboratory test done for routine hemogram, total count differential count, hemoglobin percentage, liver function tests, serum urea, creatinine, viral markers, and C-reactive protein were recorded at baseline.
The primary end point was a reduction in UAS after 8 weeks of injection serum and histaglobulin. The proportion of patients who achieved complete remission at 24 weeks of therapy was noted. The baseline UAS was calculated as an average of daily scores for the 7 days at the screening visit. Similarly, during each visit, UAS was calculated as an average of daily scores for the preceding 7 days. Reduction in the requirement of antihistamine tablets was also noted.
Data were entered and analyzed using GraphPad software (California corp, USA). Mann–Whitney test was used to compare the means between two groups. Wilcoxon signed-rank test was used to compare pre- and posttreatment UAS scores.
| Results|| |
During the study period, a total of 72 patients were diagnosed with chronic urticaria, but 60 patients had completed the stipulated 8 weeks of treatment. They were divided into Group A and Group B after ASST. Demographic details are mentioned in [Table 1] and [Table 2] and flowchart study [Figure 3].
|Table 2: Urticaria activity score and autologous serum skin test status in both groups|
Click here to view
|Figure 3: Flow chart of the study. UAS = Urticaria activity score, Group A = Serum, Group B = Histaglobulin|
Click here to view
In patients of Group A, the efficacy end point was a mean reduction in UAS from 68.5% to 29% and in patients of Group B mean UAS value reduced from 69.4% to 39.4% by 8 weeks [Table 3].
|Table 3: Reduction in number and urticaria activity score at baseline and 8 weeks in both groups|
Click here to view
We observed reduction in the UAS score during each week in both groups which was also found to be statistically significant by Dunn's multiple comparison test [Figure 4]. The onset of response was observed in the 2nd week in both groups, but it was clinically significant at the 4th week in Group A and 5th week in Group B.
Mean reduction in UAS in both groups was statistically significant at 8 weeks. The difference in response between these two groups was measured by Mann–Whitney test and considered statistically significant (P = 0.0168) [Table 4] and [Figure 5].
|Table 4: Weekly reduction in urticaria score in group A(serum) and group B (histaglobulin)|
Click here to view
|Figure 5: Mean reduction urticaria activity score at baseline and at 8 weeks|
Click here to view
ASST test was carried out in both groups prior to the study, and the mean reduction in UAS score among ASST-positive and ASST-negative cases is mentioned in [Table 5].
|Table 5: Weekly comparison of autologous serum therapy and histaglobulin in autologous serum skin test positive and negative patients|
Click here to view
Among 30 patients of Group A who completed therapy, complete remission (UAS = 0) was observed in three patients at 8 weeks and none in Group B. Excellent response (≥75% reduction) was observed in eight patients of serum therapy and two patients of histaglobulin therapy; good response (51%–74% reduction) was observed in eight patients of serum therapy and five patients of histaglobulin therapy; moderate response (25%–50% reduction) was observed in 11 patients of serum therapy and 16 patients of histaglobulin therapy; and poor response (<25% reduction) was observed in three patients of serum therapy and seven patients of histaglobulin therapy. During follow-up period, two patients of serum therapy had attained complete remission.
As mentioned in methods, we have enrolled patients with moderate and severe UAS score.
All patients in both groups enter into the mild and moderate score, and none of the patients remain in severe score; thus, improvement was observed in both groups [Table 3].
No life-threatening therapy-related adverse effect was noted either during or after the treatment in both groups. However, urticaria activity continued to remain at a low level among the study participants, and during follow-up period, three patients of Group A and six patients of Group B had a recurrence of the symptom.
| Discussion|| |
Chronic urticaria has endless clinical course and presentation and it was also troublesome for the patient. Treatment of chronic urticaria challenging task for the physician. In the pathogenesis of urticaria, mast cell degranulation plays a crucial role; however, the reason for degranulation is sometime unknown. In recent times, antibody to high-affinity IgE receptor (FcɛRI) is identified and found to degranulate the mast cells by cross-linking the IgE receptors. This entity is known as autoreactive urticaria and it accounts for 27%–61% of chronic urticaria.
Second-generation antihistamines remain the mainstay of treatment. Even if it provides immediate relief from symptoms, it does not affect the immune pathogenesis. Different immunological agents that are being used are oral corticosteroids, cyclosporine, methotrexate, intravenous immunoglobulin, omalizumab, and tacrolimus., They act by preventing antibody formation thereby decrease deganulation. There were few studies which used these drugs, but the cost of this drugs and side effects makes its utility limited.
AST and histaglobulin both are immunological treatment, so thinking of this basic mechanism, we chose to use autologous serum and histaglobulin as therapeutic methods.
In this study, AST group shows a better reduction in UAS than histaglobulin group and reduces the burden of antihistamines.
We could not find the use of these two modalities in a single study after searching PubMed, Google Scholar, and ScienceDirect.
[Table 6] shows a comparison of different immunological agents with the present study.
In case of serum therapy, a study by Bajaj et al. shows a mean reduction in UAS more in ASST-positive patients whereas we found a mean reduction in UAS more in ASST-negative patients. However, we have fewer ASST-positive patients (6 out of 30) who were in serum group. In few studies, they took follow-up period up to 2 years in our study, and we have only follow-up period of 16 weeks. During that, few patients were a dropout and three patients relapsed after 1 month of treatment in Group A.
Previously, whole blood therapy is used for many autoimmune diseases such as pemphigus, severe dry eye (Sjogren's syndrome and rheumatoid arthritis), cancer, and allergic disease like atopic dermatitis.
Tseng et al. who used whole blood as therapy in chronic urticaria reported minor side effects such as bruising and soreness at injection site and also few patients developed worsening of symptom at the end than baseline., We did not notice any above similar complaint in our patients, but four patients developed wheals after the injection.
The autologous serum has circulating autoreactive factor and is given by fine needle to reduce injection site pain in contrast to whole blood in which the above factor is absent and injections are more painful. The mechanism by AST works in pemphigus by inhibiting disease inducing antibodies and also shifts Th2 cytokine profile to Th1 in urticaria. Bajaj et al. used the serum as a modification of whole blood therapy in chronic urticaria. Godse et al. used serum as subcutaneous injection.
Histaglobulin is capable of eliciting an immunological response with the production of highly potent antihistaminic antibodies. The antihistamine antibodies formed will neutralize the released histamine and eliminate urticaria effectively.
Histaglobulin is a lyophilized sterile preparation of histamine dihydrochloride coupled to active protein fraction extracted from human blood (gamma globulin) in strictly defined proportions, which is a useful alternative. Gamma-globulin used in HISTOGLOB® is tested negative for hepatitis B surface antigen, HIV-1 and HIV-2 antibodies, and hepatitis C virus-ribonucleic acid by polymerase chain reaction as declared by the manufacturer.
Rajesh et al. showed a marked reduction in UAS (80%) and complete remission (45%) in patients of receiving histaglobulin injection. Our figure was very lower than their result. However, these two studies are not easily comparable as they did not divide patients into ASST-positive and ASST-negative group. In our study, during follow-up period, six patients develop relapse within 3–4 weeks after the treatment in Group B.
Histaglobulin has been widely used in the treatment of allergic rhinitis and in various allergic disorders such as asthma, atopic dermatitis, chronic urticaria (CU), erythema multiforme, and cutaneous drug allergy.
In our study, we found a good response in both groups irrespective of their ASST status; this raised the question about the plausibility of ASST as a reliable test to detect autoreactive urticaria. Positive ASST was also found in a normal individual, a person having Helicobacter pylori antibodies and person sensitive to non steroidal anti-inflammatory drugs. Hence, we needed another test in the future for research of autoreactive urticaria.
Our study emphasizes that AST is cost-effective and useful alternative to other treatment modalities and also gives longer treatment-free interval as AST has a low relapse rate compared to histaglobulin. ASST-negative patients also showed an effective result with both treatments.
In this study, we have a small sample size and thus less number of ASST-positive patients in Group A. Due to randomization, they fall unevenly in both groups, so our result was affected by that figure. There was also dropout of participants on follow-up period.
| Conclusion|| |
Patients of chronic urticaria get more relief during treatment and it has long-term treatment-free period too. No adverse effects were noted with any of the drugs. They both can be used as an alternative to the immunosuppressive agents. We also noted patient satisfaction with this type of therapeutic modalities.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Mehta A, Godse K, Patil S, Nadkarni N, Gautam M. Treatment of refractory chronic urticaria. Indian J Dermatol 2015;60:230-7.
] [Full text]
Godse KV. Updosing of antihistamines to improve control of chronic urticaria. Indian J Dermatol Venereol Leprol 2010;76:61-2.
] [Full text]
Sánchez-Borges M, Ansotegui I, Jimenez JM, Rojo MI, Serrano C, Yañez A, et al.
Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria. World Allergy Organ J 2014;7:33.
Bajaj AK, Saraswat A, Upadhyay A, Damisetty R, Dhar S. Autologous serum therapy in chronic urticaria: Old wine in a new bottle. Indian J Dermatol Venereol Leprol 2008;74:109-13.
] [Full text]
Rajesh G, Keerthi S, Karthikeyan K, Venkatesan M. Weekly injection of histaglobulin produces long-term remission in chronic urticaria: A prospective clinical study. Indian J Pharmacol 2016;48:292-7.
] [Full text]
Inamadar AC, Palit A. Management of autoimmune urticaria. Indian J Dermatol Venereol Leprol 2008;74:89-91.
] [Full text]
Vohra S, Sharma NL, Mahajan VK. Autologous serum skin test: Methodology, interpretation and clinical applications. Indian J Dermatol Venereol Leprol 2009;75:545-8.
] [Full text]
Godse K. Methotrexate in autoimmune urticaria. Indian J Dermatol Venereol Leprol 2004;70:377.
] [Full text]
Pereira C, Tavares B, Carrapatoso I, Loureiro G, Faria E, Machado D, et al.
Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria. Eur Ann Allergy Clin Immunol 2007;39:237-42.
Staubach P, Onnen K, Vonend A, Metz M, Siebenhaar F, Tschentscher I, et al.
Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: A placebo-controlled trial. Dermatology 2006;212:150-9.
Tseng JT, Lee WR, Lin SS, Hsu CH, Yang HH, Wang KH, et al
. Autologous serum skin test and autologous whole blood injections to patients swith chronic urticaria: A retrospective analysis. Dermatol Sin 2009;27:27-36.
Brewer DD. A systematic review of autohemotherapy as a treatment for urticaria and eczema. Cureus 2014;6:e233.
Godse KV, Nadkarni N, Patil S, Mehta A. Subcutaneous autologous serum therapy in chronic spontaneous urticaria. Indian J Dermatol 2017;62:505-7.
] [Full text]
Gushchin IS, Luss LV, Il'ina NI, Larina ON, Pakhomova LA. Therapeutic effectiveness of histaglobin preparations in patients with allergic rhinitis and chronic urticaria. Ter Arkh 1999;71:57-62.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6]